You are here

Daiichi Sankyo

Roche nets FDA approval for HER2-low breast cancer test paired with AstraZeneca-Daiichi's Enhertu

Fierce Biotech

Wed, 10/5/22 - 07:07 pm

HER2-low breast cancer

Daiichi Sankyo's Ezharmia Becomes First EZH1/2 Inhibitor for Blood Cancer

BioSpace

Mon, 09/26/22 - 11:32 pm

relapsed or refractory adult T-cell leukemia/lymphoma

ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC

Fierce Biotech

Mon, 09/12/22 - 10:43 am

small cell lung cancer

Seagen loses arbitration case to Daiichi Sankyo over cancer drug technology

BioPharma Dive

Sun, 08/14/22 - 10:50 pm

FDA approves AstraZeneca, Daiichi drug in breast cancer first

BioPharma Dive

Sun, 08/7/22 - 11:24 pm

HER2-low breast cancer

AstraZeneca wins two recommendations, one priority review

Morningstar

Mon, 07/25/22 - 10:54 am

Daiichi Sankyo willfully infringed Seagen patent in creating Enhertu, court rules

Fierce Pharma

Wed, 07/20/22 - 09:58 am

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

Pharmaforum

Mon, 06/13/22 - 10:44 am

clinical trials

acute myeloid leukemia

ASCO22: Enhertu aces key HER2-low test in breast cancer

Pharmaforum

Mon, 06/6/22 - 09:43 am

HER2-low breast cancer

Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges

Endpoints

Tue, 05/31/22 - 10:39 am

insider trading

The 12 Top Biotech Companies Hiring Now

BioSpace

Tue, 05/10/22 - 10:26 pm

Moderna Therapeutics

Waters Corporation

Gilead Sciences

Emergent BioSolutions

FDA Approves AstraZeneca, Daiichi Sankyo’s ENHERTU in Breast Cancer

Contract Pharma

Thu, 05/5/22 - 10:40 am

HER2+ breast cancer

FDA starts speedy review of Enhertu in lung cancer

Pharmaforum

Tue, 04/19/22 - 10:54 am

non-small cell lung cancer

Seagen scores $41.8M in Enhertu patent case against Daiichi Sankyo

Fierce Pharma

Mon, 04/11/22 - 11:00 am

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

Pharmaforum

Mon, 02/21/22 - 10:35 am

clinical trials

HER2-low breast cancer

Daiichi makes play for share of Japan’s COVID booster market

Pharmaforum

Mon, 01/31/22 - 10:49 am

Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development

Endpoints

Wed, 01/12/22 - 11:26 pm

Biopharma developments over the Christmas period

EP Vantage

Mon, 01/3/22 - 10:26 am

Alnylam Pharmaceuticals

Bio-Thera Solutions

BridgeBio Pharma

Madrigal Pharmaceuticals

Sutro BioPharma

Tasly Pharmaceutical Group

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

Pharmaforum

Thu, 12/23/21 - 11:53 am

antibody-drug conjugate

patritumab deruxtecan

AZ, Daiichi take aim at Gilead in triple-negative breast cancer

Pharmaforum

Wed, 12/8/21 - 10:37 am

Gilead Sciences

triple negative breast cancer

Pages